Cargando…

Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020

OBJECTIVES: To evaluate the incremental value of new drugs across disease areas receiving favourable coverage decisions by the UK’s National Institute for Health and Care Excellence (NICE) over the past decade. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study assessed favourable apprais...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polak, Tobias B, Cucchi, David GJ, Darrow, Jonathan J, Versteegh, Matthijs M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996039/ https://www.ncbi.nlm.nih.gov/pubmed/35396306 http://dx.doi.org/10.1136/bmjopen-2021-058279

Ejemplares similares

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
por: Ford, John A, et al.
Publicado: (2012)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Letters to the Editor. Benefits to UK of staying in CERN
Publicado: (1984)

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
por: Versteegh, Matthijs
Publicado: (2016)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

The NICE Evidence Standards Framework for digital health and care technologies – Developing and maintaining an innovative evidence framework with global impact
por: Unsworth, Harriet, et al.
Publicado: (2021)

Institutional framework for integrated Pharmaceutical Benefits Management: results from a systematic review
por: Hermanowski, Tomasz Roman, et al.
Publicado: (2015)

A change in the NICE guidelines on antibiotic prophylaxis: British Heart Valve Society update
por: Chambers, John B, et al.
Publicado: (2017)

Randomized Incremental Construction of Delaunay Triangulations of Nice Point Sets
por: Boissonnat, Jean-Daniel, et al.
Publicado: (2020)

An Appraisal of Incremental Learning Methods
por: Luo, Yong, et al.
Publicado: (2020)

Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK
por: Ding, Xuejie, et al.
Publicado: (2021)

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

Impact of the National Institute for Health and Care Excellence (NICE) guidance on medical technology uptake: analysis of the uptake of spinal cord stimulation in England 2008–2012
por: Vyawahare, Bharati, et al.
Publicado: (2014)

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
por: Ozieranski, Piotr, et al.
Publicado: (2020)

UK must invest in quantum technology
por: Cartlidge, E
Publicado: (2001)

Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
por: de Groot, Saskia, et al.
Publicado: (2015)

BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres
por: van Ommen, Gert-Jan B, et al.
Publicado: (2015)

A decade of integration and collaboration: the development of integrated health care in Sweden 2000–2010
por: Ahgren, Bengt, et al.
Publicado: (2011)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Why the UK should invest in accelerator technology
por: Peach, Kenneth J
Publicado: (2000)

Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund.
por: Sharma, Tarang, et al.
Publicado: (2018)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

Soft Targets: Nurses and the Pharmaceutical Industry
por: Jutel, Annemarie, et al.
Publicado: (2008)

Greater than the sum of our parts? Emerging lessons for UK health and social care
por: Glasby, Jon, et al.
Publicado: (2008)

Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK
por: Wu, Runguo, et al.
Publicado: (2021)

Industry views of the UK Soft Drinks Industry Levy: a thematic analysis of elite interviews with food and drink industry professionals, 2018–2020
por: Jones, Catrin P, et al.
Publicado: (2023)

Increasing transparency and accountability in national pharmaceutical systems
por: Paschke, Anne, et al.
Publicado: (2018)

Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study
por: Mpofu, Philani, et al.
Publicado: (2023)

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
por: Hale, George, et al.
Publicado: (2023)

Moving Pharmacy Benefits from Nice to Have to Essential Benefits
por: Caldwell, Kim A., et al.
Publicado: (2020)

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
por: Kaltenthaler, Eva, et al.
Publicado: (2016)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0sbnmsaaq5i89nanvfhcji2gci